New therapeutic targets in pancreatic cancer

Pancreatic adenocarcinoma (PDAC) is the most common type of pancreatic cancer (PC) [1 –3]. PDAC incidence is rising; it is expected to become the second cause of cancer-related death by 2030 and has a very poor prognosis[4]. More than 80% of patients have an advanced disease at diagnosis, and the 5-year overall survival rate is approximately 7% [5]. Poor survival is attributed to h igh aggressiveness, intrinsic chemotherapeutics resistance and lack of effectively targetable oncogenic drivers. Systemic chemotherapy is the mainstay of locally advanced (LAPC) and metastatic (MPC) patients treatment and single-agent gemcitabine had been the standard for more than two decades until first-line FOLFIRINOX and nab-paclitaxel/gemcitabine demonstrated better efficacy[6–9].

Source: Cancer Treatment Reviews - November 10, 2019 Category: Cancer & Oncology Authors: Eleonora Lai, Marco Puzzoni, Pina Ziranu, Andrea Pretta, Valentino Impera, Stefano Mariani, Nicole Liscia, Paolo Soro, Francesca Musio, Mara Persano, Clelia Donisi, Simona Tolu, Francesca Balconi, Annagrazia Pireddu, Laura Demurtas, Valeria Pusceddu, Silv Tags: Tumour Review Source Type: research